CYT-107 is under clinical development by RevImmune and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CYT-107’s likelihood of approval (LoA) and phase transition for Sepsis took place on 02 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CYT-107 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CYT-107 overview

CYT-107 is under development for coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in lymphopenic patients, nontuberculous mycobacteria lung disease including mycobacterium avium complex or mycobacterium abscessus complex, and metastatic transitional urothelial tract cancer. The drug candidate is administrated through subcutaneous, intramuscular and intravenous route as a liquid solution. It is a glycosylated recombinant human interleukin-7. It was under development for the treatment of high grade glioma, HIV infections, hepatitis C, hepatitis B, idiopathic CD4 lymphocytopenia, sepsis and progressive multifocal leuko-encephalopathy (PML), renal cell carcinoma, metastatic breast cancer and metastatic melanoma.

RevImmune overview

RevImmune formerly known as Cytheris is a biopharmaceutical company. The company is into research and development of medicines for immune modulation. It focuses on treating lymphopenia-driven diseases. RevImmune offers drugs to improve the immune system of patients suffering from chronic viral infections, cancer such as HCV, HBV, and HIV. The company’s clinical trials include IL-7 oncology trials, IL-7 HIV trials, and other IL-7 trials. It also has various ongoing product development projects such as IL-7 in oncology, IL-7 in HIV, IL-7 in HBV, and IL-7 in HCV. Its investors include Bioam, CDC Entreprises and the FSI, Innovation capital, and Forbion Capital Partners. RevImmune is headquartered in Issy-les-Moulineaux, France.

Quick View CYT-107 LOA Data

Report Segments
  • Innovator
Drug Name
  • CYT-107
Administration Pathway
  • Intramuscular
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Hematological Disorders
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.